De som köpt den här boken har ofta också köpt Brave New Words av Salman Khan (inbunden).
Köp båda 2 för 3983 kr"This book is a must-have for anyone dealing with dementia in their clinical practice or research." --Doody
Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries. Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King's College Hospital and Emeritus Professor of Nutritional Biochemistry at King's College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King's College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the ...
DIAGNOSIS AND MANAGEMENT IN DEMENTIA
I. Dementia: Introductory Chapters and Setting the Scene1. Mixed dementia: an overview; 2. Vascular dementia: an overview; 3. Small vessel disease and dementia; 4. Linking Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia; 5. Mortality in dementia: linking in delirium; 6. Midlife diabetes and the risk of dementia- understanding the link; 7. Gait and Alzheimer's disease /Gait and dementia; 8. Hypertension and dementia; 9. Genetics of dementia: focus on Alzheimer's disease; 10. Clinical and pathological phenotypes in autosomal dominant frontotemporal dementia; 11. Risk factors in dementia: genetic and nongenetic; 12. Lipidomics and biomarker in Alzheimer's disease; 13. The 5xFAD mouse model of Alzheimer's disease
II. Biomarkers, Psychometric Instruments and Diagnosis14. Use of cerebrospinal fluid in diagnosis of dementia; 15. Salivary biomarkers in Alzheimer's disease; 16. Diacylglycerols as biomarkers in dementia; 17. Butyrylcholinesterase (BChE) as a biomarker in Alzheimer's disease; 18. Blood brain-derived neurotrophic factor as a biomarker of Alzheimers disease; 19. Methods of amyloid PET Imaging and its applications to Alzheimer's disease spectrum; 20. Applications of diffusion-weighted imaging (DWI) Tractography and Alzheimer's disease; 21. Transcranial Magnetic stimulation and diagnostic applications to dementias; 22. Retinal imaging and dementia as a diagnostic tool; 23. The prediction of Alzheimer's disease; 24. Addenbrooke's Cognitive Examination; 25. The Montreal Cognitive Assessment (MoCA) and applications to dementia; 26. ALBA Screening Instrument (ASI) and applications to dementia; 27. The Quick Mild Cognitive Impairment (Qmci) screen and applications to dementia; 28. Assessment of activities of daily living (ADL) applied to dementia
III. Pharmacological Treatments for Dementia29. Cholinesterase inhibitors in dementias: an overview; 30. Choline-containing phospholipids and treatment of adult-onset dementia disorders; 31. Donepezil usage: a focused review; 32. Memantine: a focused review; 33. The benefits of calcium channel blockers for the therapy of dementia; 34. Pitfalls for pharmacotherapeutic trials in dementia; 35. All-trans retinoic acid in Alzheimer's disease; 36. Dementias and usage of NMDA receptor antagonists; 37. Dementia and bladder dysfunction: a focus on treatments with anticholinergics; 38. Linking astrocytes' exosomes to Alzheimer's pathogenesis and therapy; 39. Changing the fate: therapeutic mechanisms focus on the switch of beta-amyloid precursor protein (APP) processing; 40. Acetylcholinesterase inhibitory agents in plants and application to dementia: Alzheimers Disease; 41. Removal of blood amyloid as a safety strategy
IV. Non-Pharmacological Treatments and Procedures42. Caring for people with Dementia in the Acute Hospital; 43. Environmental enrichment in dementia; 44. Music therapy in dementia; 45....